Research Ethics Committee Reference Number	IRAS number	Full Name of Trial	Target number of patients available?	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Target date to recruit patients agreed?	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date trial closed to recruitment	Total number of patients recruited when recruitment ended	Reason for the closure of the trial
12/NE/0198	100141	A Multicentre, Single-Blind, Randomised Parallel-Group Study to Assess the Short and Long-Term Efficacy of Certolizumab Pegol plus Methotrexate Compared with Adalimumab plus Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate	Range agreed	3	5	Not available / not agreed		1	13/01/2016	1	Withdrawn by Sponsor
14/WM/1210	164208	A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects.	Number agreed	4	4	Date agreed	12/08/2015	11	29/01/2016	11	Recruitment finished
15/LO/1239	184169	A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects.	Number agreed	5	5	Date agreed	31/03/2016	3	02/02/2016	3	Withdrawn by Sponsor
14/NE/1185	152820	Short duration of dual antiplatElet therapy with SyNergy® II everolimus eluting stent in patients Older than 75 years undergoing percutaneous coronary Revascularization. The SENIOR trial	Range agreed	15	40	Date agreed	30/06/2015	7	11/02/2016	7	Recruitment finished
13/NE/0336	137605	Trial of Proton Pump Inhibitors in Throat Symptoms	Number agreed	50	50	Date agreed	01/10/2017	9	12/02/2016	9	Withdrawn by Sponsor
13/EE/0335	137965	COOL-AMI EU CASE SERIES CLINICAL STUDY: a single-centre case series clinical study to assess the feasibility of integrating therapeutic hypothermia(TH)using the ZOLL IVTM System as an adjuvant therapy in percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI)	Range agreed	5	7	Date agreed	28/02/2016	4	26/02/2016	4	Withdrawn by Sponsor
14/SS/1048	154401	A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease	Number agreed	5	5	Date agreed	10/07/2015	5	01/03/2016	5	Recruitment finished
13/NW/0316	124757	Phase 4 trial comparing cumulative incidence of SCC after treatment + ingenol mebutate & imiquimod for multiple actinic keratoses on face &scalp. A multi-centre, randomised, two-arm, open label, active-controlled, parallel group, 36-month trial.	Number agreed	8	8	Date agreed	31/05/2015	10	31/03/2016	10	Recruitment finished
14/NW/1531	165328	Comparative Testing of 3 mL TransFix/EDTA Vacumm Blood Collection Tubes (TVTs) and Cyto-Chex 5 mL Blood Collection Tubes (BCTs) Part 1: Equivalence Study	Number agreed	10	10	Date agreed	05/11/2015	13	19/04/2016	13	Recruitment finished
15/YH/0045	168195	ABLATOR Ablation Observational Registry	Range agreed	25	100	Date agreed	17/07/2017	36	28/04/2016	36	Recruitment finished

14/LO/1443	149317	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis Converted from Epoetin or Darbepoetin Alfa Treatment	Number agreed	4	4	Date agreed	19/12/2017	1	28/04/2016	1	Withdrawn by Sponsor
13/EM/0348	122371	Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan® 0.01 % with ocular surface intolerance	Number agreed	6	6	Date agreed	30/04/2016	2	30/04/2016	2	Recruitment finished
16/LO/0039	195230	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV 1 Infected Subjects who are Virologically Suppressed	Number agreed	5	5	Not available / not agreed		2	03/06/2016	2	Withdrawn by Sponsor
15/EE/0322	183313	A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P)	Number agreed	3	3	Date agreed	29/02/2016	1	10/06/2016	1	Recruitment finished
16/LO/0036	195359	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults	Number agreed	6	6	Not available / not agreed		5	10/06/2016	5	Withdrawn by Sponsor
13/SC/0279	124704	A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV1 Positive Subjects.	Number agreed	4	4	Not available / not agreed		4	16/06/2016	4	Recruitment finished
16/LO/0026	195795	A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults	Number agreed	4	4	Not available / not agreed		3	22/06/2016	3	Withdrawn by Sponsor
16/LO/0240	199083	An open-label, prospective, non randomised, multicentre study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300 mg s.c. with or without previous exposure to systemic therapy	Number agreed	4	4	Date agreed	30/06/2017	4	28/06/2016	4	Recruitment finished
15/SC/0280	170452	Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral antIcoagulation sTrategy (The RE-CIRCUIT Trial)	Range agreed	9	20	Date agreed	31/08/2016	8	29/06/2016	8	Recruitment finished
14/WM/1128	150126	Prognostic biomarkers in HCV cirrhosis	Number agreed	20	20	Date agreed	30/12/2016	15	01/07/2016	15	Withdrawn by Sponsor
14/LO/2218	161762	Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer.	Number agreed	4	4	Date agreed	31/03/2016	0	25/07/2016	0	Withdrawn by Host
15/LO/0564	173148	ARMOR3-SV: A Phase 3, Randomized, Open-Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) with Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)	Number agreed	2	2	Date agreed	01/02/2017	0	26/07/2016	0	Withdrawn by Sponsor
15/LO/0684	177109	Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension	Number agreed	5	5	Date agreed	13/10/2015	1	27/07/2016	4	Recruitment finished

15/LO/0881	177217	A Phase III Multicenter, Double Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evluate the Safety and Efficacy of MK-149A One Daily Versus ATRIPLA Once-Daily in Treatment Naïve HIV - 1 Infected Subjects	Number agreed	5	5	Date agreed	28/02/2018	5	08/08/2016	5	Recruitment finished
15/LO/1324	181497	AMPLATZER Amulet Observational Post-Market Study	Number agreed	10	10	Date agreed	17/11/2019	19	24/08/2016	19	Recruitment finished
09/HO709/56	27957	Plasma Exchange and glucocorticoid in anti_neutrophil cytoplasm antibody associated vasculitis : a randomised controlled trial	Number agreed	3	3	Date agreed	01/09/2016	5	30/09/2016	5	Recruitment finished
14/YH/0086	147377	RESPOND: Repositionable Lotus Valve System-Post Market Evaluation of Real World Clincial Outcomes	Range agreed	15	30	Date agreed	31/12/2015	121	01/10/2016	127	Recruitment finished
15/LO/1600	182262	A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2−BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY	Number agreed	6	6	Date agreed	02/03/2018	1	04/10/2016	1	Withdrawn by Sponsor
16/NI/0034	194752	The Medtronic CoreValve™ Evolut R™ FORWARD Study	Number agreed	5	5	Date agreed	01/08/2017	11	01/11/2016	11	Recruitment finished
16/EE/0098	201052	DIASOLVE: A randomised, crossover investigation to evaluate and compare the effectiveness, safety and feasibility of a novel dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for measuring fractional flow reserve (FFR) using intra-coronary non-weight adjusted adenosine infusion with the standard intra-venous administration of adenosine, in subjects with intermediate coronary artery stenosis.	Number agreed	5	5	Date agreed	30/11/2016	7	10/11/2016	7	Recruitment finished
13/NW/0002	114402	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL? Haemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery	Range agreed	10	32	Date agreed	28/02/2014	5	22/11/2016	32	Recruitment finished
13/NI/0138	120046	Portico I Study International long-term follow-up study of patients	Number agreed	10	10	Date agreed	30/06/2018	10	01/12/2016	10	Recruitment finished